Indeed, circulating cytokines in patient plasma such as interleukin-6 (IL-6), IL-8, and IL-10 were implicated in poor patient responses to ICBs in patients with kidney, breast, and bladder cancer and melanoma (12, 13). This evidence concerns the gene IL6 and melanoma.